[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"gastric-carcinoma\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:gastric-carcinoma":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,13,0,[8,43,78,109,133,156,182,205,240,263,283,310,331],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100393996","patient-derived-xenografts-to-reduce-cancer-health-disparities-100393996",false,"NCT04410302","Patient-Derived Xenografts to Reduce Cancer Health Disparities","University of California Minority Patient-Derived Xenograft (PDX) Development and Trial Center (UCaMP) to Reduce Cancer Health Disparities","Inclusion Criteria:\n\n* Patient receiving treatment for the above 4 cancers (bladder cancer, lung cancer, gastric\u002Fstomach cancer, and liver cancer)\n* Signed informed consent that will be put on file\n\nExclusion Criteria:\n\n* No informed consent obtained\n* Specimen unacceptable\u002Fdegraded\u002Fetc.\n* Individuals who are not yet adults (infants, children, teenagers)\n* Pregnant women\n* Prisoners\n* Adults unable to consent","ALL","21 Years","100 Years",{"count":20,"type":21},500,"ESTIMATED","OBSERVATIONAL","This trial establishes patient-derived cancer xenografts in addressing cancer health and treatment disparities that disproportionately affect racial\u002Fethnic minorities. Understanding the genetic and response differences among racial\u002Fethnic minorities may help researchers enhance the precision of therapeutic treatments.",[25,26,27,28,29],"Bladder Carcinoma","Gastric Carcinoma","Liver and Intrahepatic Bile Duct Carcinoma","Lung Carcinoma","Malignant Neoplasm","RECRUITING","2026-08-18",{"date":33,"type":34},"2026-08-20","ACTUAL",{"date":36,"type":34},"2019-11-12",{"date":38,"type":21},"2027-06",{"name":40,"class":41},"University of California, Davis","OTHER",2,{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":47,"acronym":4,"eligibilityCriteria":48,"healthyVolunteers":49,"sex":16,"minAge":50,"maxAge":51,"enrollmentInfo":52,"targetDuration":4,"studyType":54,"phases":55,"briefSummary":57,"conditions":58,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":77},"100592628","the-vanguard-study-testing-a-new-way-to-screen-for-cancer-100592628","NCT06995898","The Vanguard Study: Testing a New Way to Screen for Cancer","Inclusion Criteria:\n\n* Ages 45-75 years old\n* Agree to provide blood samples for possible MCD testing at enrollment and at 1 year following enrollment\n* Agree to allow collection of information from their medical records for study-related purposes\n* Understand and be able to complete informed consent and participant questionnaires in English, Spanish, or Arabic\n\n  * Note: Eligibility for Spanish and Arabic languages are at the Hub's discretion\n\nExclusion Criteria:\n\n* Solid malignant tumor or blood cancer diagnosis, with or without treatment, within the last 5 years\n\n  * Note: Persons with a history of in situ cancers (e.g., ductal carcinoma in situ of the breast, cervical cancer in situ, atypical melanocytic hyperplasia or melanoma in situ) or nonmelanoma skin cancer are eligible. Persons with a history of prostate cancer that has not been treated are not eligible, regardless of when the diagnosis occurred\n* Ongoing cancer diagnostic work-up\n* Ongoing participation in another study of an investigational cancer screening test or technology not currently utilized in routine clinical practice\n* Currently breastfeeding or pregnant, or planning to become pregnant in the next year\n* History of solid organ or hematopoietic transplantation at any time, or blood transfusion within the last 30 days",true,"45 Years","75 Years",{"count":53,"type":21},24000,"INTERVENTIONAL",[56],"NA","The Vanguard Study is a feasibility study to explore several aspects of evaluating multi-cancer detection (MCD) tests in a future definitive randomized controlled trial. An MCD test measures markers in the blood in order to screen for multiple cancers simultaneously. There is a need to understand how MCDs may work as cancer screening tools. The goal of cancer screening is to reduce the burden of cancer by identifying cancers before they show symptoms or signs, when treatment is likely to be most effective. In this study, adults aged 45-75 without cancer will be randomly assigned to one of 3 groups: 2 separate MCD test groups or a control group. These two MCD tests will not be compared to each other but will be compared to cancers detected in the control group. This study will provide early information on how well MCD tests perform as cancer screening tools. It will also help researchers understand how patients and their doctors make decisions about their care when the MCD test result comes back as normal (negative) or abnormal (positive).",[25,59,60,61,26,62,28,63,64,65,66],"Breast Carcinoma","Colorectal Carcinoma","Esophageal Carcinoma","Liver Carcinoma","Malignant Solid Neoplasm","Ovarian Carcinoma","Pancreatic Carcinoma","Prostate Carcinoma","2026-08-13",{"date":69,"type":34},"2026-08-14",{"date":71,"type":34},"2025-06-18",{"date":73,"type":21},"2029-06-30",{"name":75,"class":76},"National Cancer Institute (NCI)","NIH",40,{"id":79,"slug":80,"hasResults":11,"nctId":81,"briefTitle":82,"officialTitle":83,"acronym":4,"eligibilityCriteria":84,"healthyVolunteers":49,"sex":16,"minAge":85,"maxAge":4,"enrollmentInfo":86,"targetDuration":4,"studyType":54,"phases":88,"briefSummary":89,"conditions":90,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":99,"lastUpdatePostDateStruct":100,"startDateStruct":102,"completionDateStruct":104,"leadSponsor":106,"locationsCount":108},"100614772","studying-the-pagoda-algorithm-for-chemotherapy-dose-changes-to-prevent-unplanned-treatment-delays-100614772","NCT07283939","Studying the PAGODA Algorithm for Chemotherapy Dose Changes to Prevent Unplanned Treatment Delays","PAGODA: Randomized Trial of a Proactive Graduated Dose Modification Algorithm for FOLFOX Chemotherapy to Prevent Unplanned Delays","Inclusion Criteria:\n\n* \\* REGISTRATION ELIGIBILITY CRITERIA (STEP 1)\n\n  * Histologic confirmation of invasive cancer that is confirmed or suspected to arise from the gastrointestinal (GI) tract\n  * Any stage for which FOLFOX-based chemotherapy is a clinically-indicated, standard-of-care treatment (adjuvant, neoadjuvant, or first-line chemotherapy)\n  * Eligible primary tumor sites include the esophagus, gastroesophageal junction, stomach, small intestine, ampulla of Vater, appendix, colon, rectum, and cancers of unknown primary with suspected GI origin\n  * Prior systemic therapy for GI cancer (other than cycle 1 of FOLFOX-based chemotherapy) is not allowed. Prior radiation-sensitizing chemotherapy is permitted\n  * The planned duration of FOLFOX-based chemotherapy must be at least four cycles (1 cycle = 14 days)\n  * Cycle 1, day 1 of FOLFOX-based chemotherapy must be completed 1 to 8 days prior to registration\n  * Cycle 1, day 1 of FOLFOX-based chemotherapy must include minimum ordered doses of oxaliplatin (≥ 65 mg\u002Fm\\^2) and infusional 5-FU (2400 mg\u002Fm\\^2\u002F46 hours). Use of the 5-FU bolus is at the discretion of the treating physician\n  * Patients who require primary prophylactic white blood cell growth factor with cycle 1 of FOLFOX chemotherapy due to high risk for fever and neutropenia are not eligible\n  * History of hypersensitivity reaction to oxaliplatin or other platinum-based drugs, to fluorouracil, or to leucovorin, and the excipients in their formulations are not eligible\n  * Age ≥ 18 years\n  * ECOG performance status ≤ 2\n  * Absolute neutrophil count (ANC) ≥ 1,000\u002Fmm\\^3\n  * Platelet count ≥ 100,000\u002Fmm\\^3\n  * Total bilirubin ≤ 3 x upper limit of normal (ULN)\n  * AST (SGOT)\u002FALT (SGPT) ≤ 5 x upper limit of normal (ULN)\n  * Calc. creatinine clearance ≥ 30 mL\u002Fmin\n  * Not pregnant and not nursing, because this study involves agents that have known genotoxic, mutagenic and teratogenic effects. Therefore, for women of childbearing potential only, a negative pregnancy test done ≤ 30 days prior to registration is required\n  * Patients with treated brain metastases are eligible if follow-up brain imaging after CNS-directed therapy shows no evidence of progression\n  * Patients with known HIV infection are eligible if receiving effective anti-retroviral therapy with undetectable viral load within 6 months prior to registration\n  * Patients with known chronic hepatitis B virus (HBV) infection are eligible if HBV DNA is undetectable when measured within 6 months prior to registration\n  * Patients with a known history of hepatitis C virus (HCV) infection are eligible if HCV RNA is undetectable when measured at least 12 weeks after completion of antiviral therapy\n  * Patients with known history or current symptoms of cardiac disease are eligible if the New York Heart Association Functional Classification is class I or II\n  * Patients with a known history of congenital long QT syndrome are ineligible\n  * Patients with known DPD deficiency are ineligible\n* \\* NON-PATIENT (ONCOLOGY PHYSICIAN OR ONCOLOGY ADVANCED PRACTICE PROVIDER ELIGIBILITY:\n\n  * The non-patient provider participant is a medical oncologist or oncology advanced practice provider with responsibility for signing and making necessary modifications to chemotherapy orders for a subject assigned to the intervention arm (Arm B). Non-patient participants may not be enrolled more than once over the course of the study\n  * The non-patient participant must be proficient in the English language\n  * The non-patient participant must be age 21 years or older","18 Years",{"count":87,"type":21},420,[56],"This study seeks to learn whether using the PAGODA algorithm to guide chemotherapy dosing will lower the chance of unplanned delays during chemotherapy for cancer in the gastrointestinal system compared to usual care.",[91,92,93,94,61,26,95,96,97,98],"Ampulla of Vater Carcinoma","Appendix Carcinoma","Carcinoma of Unknown Primary With Gastrointestinal Profile","Colon Carcinoma","Gastroesophageal Junction Carcinoma","Malignant Digestive System Neoplasm","Rectal Carcinoma","Small Intestinal Carcinoma","2026-08-04",{"date":101,"type":34},"2026-08-05",{"date":103,"type":34},"2026-02-13",{"date":105,"type":21},"2030-05-02",{"name":107,"class":41},"Alliance for Clinical Trials in Oncology",363,{"id":110,"slug":111,"hasResults":11,"nctId":112,"briefTitle":113,"officialTitle":114,"acronym":4,"eligibilityCriteria":115,"healthyVolunteers":11,"sex":16,"minAge":85,"maxAge":51,"enrollmentInfo":116,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":118,"conditions":119,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":123,"lastUpdatePostDateStruct":124,"startDateStruct":126,"completionDateStruct":128,"leadSponsor":130,"locationsCount":132},"100634666","association-between-microplastic-exposure-and-the-pathological-progression-of-gastric-carcinogenesis-100634666","NCT07542652","Association Between Microplastic Exposure and the Pathological Progression of Gastric Carcinogenesis","Association of Microplastic Exposure With Pathological Stages of Gastric Mucosal Carcinogenesis: A Cross-Sectional Study","Inclusion Criteria:\n\n* Aged between 18 and 75 years old, gender is not restricted\n* Having a clear diagnosis result within the recent three months and being diagnosed with chronic non - atrophic gastritis, precancerous lesions of gastric cancer, or gastric cancer for the first time\n* Have clear Helicobacter pylori (Hp) test results\n* Be in normal mental state and able to independently complete the questionnaire survey\n\nExclusion Criteria:\n\n* Patients with a history of malignant tumors in other parts\n* Patients who have previously undergone upper gastrointestinal surgery, chemotherapy, or radiotherapy\n* Patients with severe diseases of major organs such as the heart, lungs liver, and kidneys\n* Patients who are currently receiving psychological intervention or taking psychiatric drugs\n* Pregnant or lactating women\n* Patients with severe missing clinical data or questionnaire information\n* Refusing to sign the informed consent form",{"count":117,"type":21},450,"The objective of this clinical trial is to explore the correlation between the level of microplastic exposure and the risk of gastric mucosal carcinogenesis, and to evaluate the strength of its effect as an independent risk factor. The main questions it aims to answer include: Does the level of microplastic exposure increase the risk of gastric mucosal carcinogenesis? Can the correlation between the level of microplastic exposure and gastric mucosal carcinogenesis, as well as the sources of high - risk microplastic exposure, be explored through a questionnaire on external microplastic exposure? Researchers will complete a design structured questionnaire and ask participants to fill it out carefully and truthfully to determine whether the level of microplastic exposure increases the risk of gastric mucosal carcinogenesis.",[26,120,121,122],"Gastritis Chronic","Intestinal Metaplasia","Gastric Precancerous Lesions","2026-04-25",{"date":125,"type":34},"2026-04-30",{"date":127,"type":34},"2026-03-31",{"date":129,"type":21},"2026-12-31",{"name":131,"class":41},"Yongquan Shi",1,{"id":134,"slug":135,"hasResults":11,"nctId":136,"briefTitle":137,"officialTitle":138,"acronym":4,"eligibilityCriteria":139,"healthyVolunteers":49,"sex":16,"minAge":140,"maxAge":141,"enrollmentInfo":142,"targetDuration":4,"studyType":54,"phases":144,"briefSummary":145,"conditions":146,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":147,"lastUpdatePostDateStruct":148,"startDateStruct":150,"completionDateStruct":152,"leadSponsor":154,"locationsCount":132},"100547457","risk-assessment-evaluation-for-identifying-participants-at-high-risk-for-stomach-cancer-100547457","NCT06408220","Risk Assessment Evaluation for Identifying Participants at High Risk for Stomach Cancer","OUR Stomach Health Project: A Pilot Study to Evaluate the Feasibility of Stomach Cancer Risk Assessment for Early Detection and Secondary Prevention","Inclusion Criteria:\n\n* Documented informed consent of the participant and\u002For legally authorized representative\n\n  * Assent, when appropriate, will be obtained per institutional guidelines\n* Age: ≥ 40 years to ≤ 80 years\n* Identify as a racial minority either Asian, Hispanic, or Black American\n* Willingness to:\n\n  * Provide blood samples and undergo upper endoscopy\n\nExclusion Criteria:\n\n* Identify as Non-Hispanic White\n* History of gastric cancer\n* Known premalignant lesions of the stomach\n* History of upper endoscopy within 2 years\n* Women of childbearing potential: Pregnant\u002F nursing\n* An employee who is under the direct\u002Findirect supervision of the principal investigator (PI)\u002Fa coinvestigator\u002Fthe study manager\n* A direct study team member","40 Years","80 Years",{"count":143,"type":21},240,[56],"This clinical trial evaluates the usefulness of various risk assessment tests, including Helicobacter pylori (H. pylori) breath testing, questionnaires, and endoscopies for identifying participants at high risk for stomach cancer. H. pylori is a bacteria that causes stomach inflammation and ulcers in the stomach. People with H. pylori infections may be more likely to develop cancer in the stomach. H. pylori breath testing can help identify the presence of H. pylori infection in a participant and help identify if the participant may be at a higher risk of developing stomach cancer. An endoscopy uses a thin, flexible lighted tube that is inserted inside the esophagus, stomach, and first part of the small intestine. This allows the doctor to see and look for abnormal areas that may need to be biopsied. Risk assessment including H. pylori evaluation, questionnaires, and endoscopies may help identify participants at high risk for stomach cancer and may be a useful screening tool for earlier stomach cancer diagnosis.",[26],"2026-03-11",{"date":149,"type":34},"2026-03-13",{"date":151,"type":34},"2024-06-27",{"date":153,"type":21},"2029-10-09",{"name":155,"class":41},"City of Hope Medical Center",{"id":157,"slug":158,"hasResults":11,"nctId":159,"briefTitle":160,"officialTitle":161,"acronym":4,"eligibilityCriteria":162,"healthyVolunteers":11,"sex":16,"minAge":85,"maxAge":163,"enrollmentInfo":164,"targetDuration":166,"studyType":22,"phases":4,"briefSummary":167,"conditions":168,"keywords":169,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":174,"lastUpdatePostDateStruct":175,"startDateStruct":176,"completionDateStruct":178,"leadSponsor":180,"locationsCount":132},"100603661","the-clinical-significance-of-examining-metastatic-lymph-nodes-in-individual-gastric-mesenteries-in-the-patients-with-gastric-cancer-undergoing-gastrectomy-100603661","NCT07139418","The Clinical Significance of Examining Metastatic Lymph Nodes in Individual Gastric Mesenteries in the Patients With Gastric Cancer Undergoing Gastrectomy","The Clinical Significance of Examining Metastatic Lymph Nodes in Respective Gastric Mesenteries in the Gastric Cancer Patients Who Received D2 Lymphadenectomy Plus Complete Mesogastric Excision","Inclusion Criteria:\n\n1. Aged older than 18 years and younger than 85 years\n2. Primary gastric adenocarcinoma confirmed by preoperative pathology result\n3. cT2-4aN0-3M0 at preoperative evaluation according to the American Joint 8 Committee on Cancer (AJCC) Cancer Staging Manual 8th Edition\n4. Patients who received gastrectomy with D2 lymphadenectomy plus complete mesogastric excision\n5. American Society of Anesthesiologists (ASA) class I, II, or III\n6. Written informed consent\n\nExclusion Criteria:\n\n1. Negative preoperative biopsy\n2. Too late tumour stage or metastasis (cT4b\u002FM1)\n3. BMI\\>30 kg\u002Fm2\n4. Total gastrectomy or proximal gastrectomy\n5. previous neoadjuvant chemotherapy or radiotherapy\n6. Previous upper abdominal surgery\n7. Combined with other malignant diseases\n8. Reject operation","85 Years",{"count":165,"type":21},400,"1 Month","This study aims to examine the predictive value of metastatic gastric mesenteries, which contains metastatic lymph node, in 6 gastric mesenteries; and importantly, to further evaluate the relationship between the number of metastatic gastric mesenteries and prognosis in the gastric cancer patients who received D2+complete mesogastric excision (CME).",[26],[170,171,172,173],"Gastric cancer","Complete mesogastric excision","Gastric mesentery","Lymph node metastasis","2026-03-08",{"date":147,"type":34},{"date":177,"type":34},"2025-10-07",{"date":179,"type":21},"2030-08-30",{"name":181,"class":41},"Jichao Qin",{"id":183,"slug":184,"hasResults":11,"nctId":185,"briefTitle":186,"officialTitle":187,"acronym":4,"eligibilityCriteria":188,"healthyVolunteers":11,"sex":16,"minAge":85,"maxAge":51,"enrollmentInfo":189,"targetDuration":4,"studyType":54,"phases":191,"briefSummary":193,"conditions":194,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":195,"lastUpdatePostDateStruct":196,"startDateStruct":198,"completionDateStruct":200,"leadSponsor":202,"locationsCount":132},"100617217","phase-3-a-study-of-disitamab-vedotin-combined-with-trastuzumab-and-tislelizumab-versus-chemotherapy-combined-with-trastuzumab-with-or-without-pembrolizumab-in-her2-high-expression-advanced-gastric-or-gastroesophageal-junction-adenocarcinoma-100617217","NCT07315750","A Study of Disitamab Vedotin Combined With Trastuzumab and Tislelizumab Versus Chemotherapy Combined With Trastuzumab With or Without Pembrolizumab in HER2-high Expression Advanced Gastric or Gastroesophageal Junction Adenocarcinoma.","A Randomized Controlled Phase III Study to Evaluate the Combination of Disitamab Vedotin, Trastuzumab, and Tislelizumab Versus Chemotherapy (CAPOX) Combined With Trastuzumab With or Without Pembrolizumab as First-Line Treatment for Advanced Gastric\u002FGastroesophageal Junction Adenocarcinoma With HER2-high Expression","Inclusion Criteria:\n\n* Voluntarily consent to participate in the study and sign the informed consent form\n* Expected survival period \\>12 weeks\n* ECOG Performance Status 0 or 1\n* Histologically confirmed unresectable locally advanced or metastatic --gastric\u002Fgastroesophageal junction adenocarcinoma\n* No prior systemic therapy for locally advanced or metastatic gastric cancer; or disease progression or recurrence occurring ≥6 months after completion of neoadjuvant\u002Fadjuvant therapy\n* HER2-high expression\n* At least one assessable lesion according to RECIST v1.1 criteria\n* Adequate organ function\n* Female subjects of childbearing potential must have a negative blood pregnancy test within 7 days prior to the first treatment, and agree not to breastfeed or donate ova from the signing of the informed consent form until 6 months after the last treatment. Male subjects must agree not to donate sperm from the signing of the informed consent form until 6 months after the last treatment.\n* Able to understand the study requirements and willing to comply with the study and follow-up procedures\n\nExclusion Criteria:\n\n* Presence of central nervous system (CNS) metastasis and\u002For carcinomatous meningitis\n* Peripheral neuropathy \\> Grade 1\n* Tumor lesions with a tendency to bleed\n* Severe gastrointestinal dysfunction that may affect drug intake, transport, or absorption\n* Bone metastases with a risk of paraplegia\n* Past or current interstitial lung disease, or severely impaired lung function\n* Other malignancies within 5 years prior to randomization, except for those expected to be cured with treatment\n* Pregnant or breastfeeding women",{"count":190,"type":21},555,[192],"PHASE3","The purpose of this study is to evaluate the efficacy and safety of Disitamab Vedotin combined with Trastuzumab and Tislelizumab Versus Chemotherapy Combined with Trastuzumab with or without Pembrolizumab as First-Line Treatment for Advanced Gastric\u002FGastroesophageal Junction Adenocarcinoma with HER2-high Expression.",[26],"2026-01-20",{"date":197,"type":34},"2026-01-21",{"date":199,"type":21},"2026-01-01",{"date":201,"type":21},"2030-12-31",{"name":203,"class":204},"RemeGen Co., Ltd.","INDUSTRY",{"id":206,"slug":207,"hasResults":11,"nctId":208,"briefTitle":209,"officialTitle":210,"acronym":211,"eligibilityCriteria":212,"healthyVolunteers":11,"sex":16,"minAge":85,"maxAge":4,"enrollmentInfo":213,"targetDuration":4,"studyType":54,"phases":215,"briefSummary":217,"conditions":218,"keywords":227,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":231,"lastUpdatePostDateStruct":232,"startDateStruct":234,"completionDateStruct":236,"leadSponsor":238,"locationsCount":132},"100565717","early-phase-1-pet-imaging-of-two-vartumabs-in-patients-with-solid-tumors-100565717","NCT06645808","PET-imaging of Two Vartumabs in Patients With Solid Tumors","The Safety, Tolerability and Biodistribution of a Single Intravenous Administration of Two Zirconium-89 Labelled Vartumabs (F8scFV or C9scFv) in Patients With Solid Tumors - a Phase 0, Open Label, PET\u002FCT Molecular Imaging Basket Trial","VARTUTRACE","General Inclusion Criteria:\n\n1. Willing to adhere to the prohibitions and restrictions specified in this protocol.\n2. Capable of giving signed informed consent (voluntarily), indicating that the patient understands the purpose and procedures required for the study and is willing to comply with the requirements and restrictions listed in the informed consent form and in this protocol.\n3. Patients aged ≥ 18 years at moment of signing informed consent form.\n4. Life expectancy of \\> 12 weeks.\n5. ECOG (Eastern Cooperative Oncology Group) performance status of 0 or 1.\n6. BMI ≥ 18.0 and ≤ 35.0 kg\u002Fm2 and weight at least 50 kg and no more than 120 kg at screening.\n7. Overtly healthy based on medical history, physical findings, vital signs, ECG at the time of screening, as judged by the Investigator. Note: one retest of vital functions and ECG is allowed within the screening window.\n8. Adequate liver- and kidney function, defined by the following laboratory results obtained during screening visit:\n\n   * AST, ALT, and alkaline phosphatase ≤ 2.5x the upper limit of normal (ULN) as determined by the UMCG laboratory reference values.\n   * Serum bilirubin ≤ 2.0x ULN as determined by the UMCG laboratory reference values. Patients with known Gilbert disease who have serum bilirubin level ≤ 3x ULN may be enrolled.\n   * INR or APTT ≤ 1.5x ULN as determined by the UMCG laboratory reference values. This applies only to patients who are not receiving therapeutic anticoagulation; patients receiving therapeutic anticoagulation should be on a stable dose.\n   * eGFR (based on plasma-creatinine) = \\>30 mL\u002Fmin.\n   * Serum albumin \\>35 g\u002FL.\n9. No other clinically significant laboratory abnormalities as determined by the investigator. Note: one retest of lab tests is allowed within the screening window.\n10. Female patients should be at least 1 year post-menopausal (amenorrhea \\>12 months and\u002For follicle-stimulating hormone \\>30 mIU\u002FmL) at screening or surgically sterile (bilateral oophorectomy, hysterectomy, or tubal ligation).\n11. Male subjects who are sexually active with a female partner of childbearing potential must agree to the use of an effective method of birth control, and must not donate sperm, until 3 months after administration of 89Zr-DFO-N-Suc-scFv (F8 or C9).\n\nMedical inclusion Criteria:\n\nColon Carcinoma:\n\n1. Patients diagnosed with colon carcinoma stage I-IV, according to the 8th edition of the TNM-classification.\n2. Histologically confirmed diagnosis of colon carcinoma.\n3. Neo-adjuvant treatment according to the standard of care.\n\nRectal Carcinoma:\n\n1. Patients diagnosed with rectal carcinoma stage I-IV, according to the 8th edition of the TNM-classification.\n2. Histologically confirmed diagnosis of rectal carcinoma.\n3. Neo-adjuvant treatment according to the standard of care.\n\nBone- and soft-tissue sarcoma\n\n1. Patients diagnosed with a bone- or soft-tissue sarcoma stage I-IV, according to AJCC staging for Sarcoma.\n2. Histologically confirmed diagnosis of sarcoma.\n3. Neo-adjuvant treatment according to the standard of care.\n\nBreast carcinoma\n\n1. Patients diagnosed with breast carcinoma stage I-IV, according to the 8th edition of the TNM-classification.\n2. Histologically confirmed diagnosis of breast carcinoma.\n3. Neo-adjuvant treatment according to the standard of care.\n\nLung Carcinoma:\n\n1. Anticipated diagnosis of Non-Small Cell Lung Carcinoma (NSCLC) stage I-IV, according to the 8th edition of the TNM-classification, based on imaging modalities such as (PET)\u002FCT or based on cytology.\n2. Neo-adjuvant treatment according to the standard of care.\n\nHead and Neck Squamous Cell carcinoma (HNSCC):\n\n1. Patients diagnosed with HNSCC of the oral cavity, oropharynx, nasal cavity, nasopharynx, hypopharynx and larynx.\n2. Histologically confirmed diagnosis of HNSCC.\n3. Neo-adjuvant treatment according to the standard of care.\n\nOesophageal and gastric carcinoma:\n\n1. Patients diagnosed with oesophagus carcinoma stage I-IV according to the 7th edition of the TNM-classification.\n2. Patients diagnosed with gastric carcinoma stage I-IV according to the 7th edition of the TNM-classification.\n3. Histologically confirmed diagnosis of oesophageal- or gastric carcinoma.\n4. Neo-adjuvant treatment according to the standard of care.\n\nPancreas carcinoma:\n\n1. Anticipated diagnosis of pancreas carcinoma stage I-IV according to the 8th edition of the TNM-classification, based on imaging modalities such as (PET)\u002FCT or based on cytology.\n2. Histologically or cytologically confirmed diagnosis of pancreas carcinoma.\n3. Neo-adjuvant treatment according to the standard of care.\n\nBladder carcinoma:\n\n1. Patients diagnosed with invasive bladder carcinoma stage I-IV according to the 7th edition of the TNM-classification.\n2. Histologically confirmed diagnosis of bladder carcinoma.\n3. Neo-adjuvant treatment according to the standard of care.\n\nGlioblastoma:\n\n1. Anticipated diagnosis of a high-grade glioma (glioblastoma, grade 4 according to the WHO classification) based on imaging modalities such as MRI and\u002For CT or a biopsy.\n2. Karnofsky performance status of at least 70%.\n3. Neo-adjuvant treatment according to the standard of care.\n\nGeneral Exclusion Criteria:\n\n1. Behavioral or cognitive impairment or psychiatric disease that, in the investigator's opinion, affects the patient's ability to understand and cooperate with the study protocol.\n2. Insufficient venous access for the study procedures.\n3. Close affiliation with the investigator, e.g. a close relative of the investigator, dependent person (e.g. employee or student), employee of the department of surgery or nuclear department of the UMCG,TRACER or affiliates.\n4. Any finding in the medical examinations or medical history giving, in the opinion of the investigator, reasonable suspicion of a disease or condition that makes treatment with the investigational drug unadvisable, or that might affect interpretation of the results of the study or render the patient at high risk for treatment complications.\n5. Participation in an interventional clinical study within 30 days prior to tracer administration that involved treatment with any drug (excluding vitamins and minerals) or medical device.\n\nMedical Exclusion Criteria:\n\n1. The existence of a second concomitant active malignancy or treatment for a second malignancy within 1 year prior to IMP-administration that is not a solid tumor indication included in the VARTUTRACE study, except for localized basal or squamous cell cancer that has been cured at least 90 days before screening.\n2. Cardiac impairment with an estimated LVEF \\\u003C35 % Prolonged QTcF (\\>450 ms), cardiac arrhythmias or any clinically significant abnormalities in the resting ECG at the time of screening, as judged by the investigator.\n3. Any abnormalities in the vital signs of the patient, as judged by the investigator, as a result of which the patient cannot participate. Note: One retest of vital functions is allowed within the screening window.\n4. Any other diseases, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug or that may affect the interpretation of the results or render the patient at high risk from treatment complications.\n5. Major surgical procedure other than for the included diagnosis within four weeks before IMP administration. Disease-related procedures, e.g. the placement of a port-a-cath, placement of a drain, ERCP, are allowed.\n6. Current evidence or history of bacterial, viral or fungal infections within 7 days before 89Zr-DFON-Suc-scFv (F8 or C9) administration as judged by the Investigator.\n\n   * T \\> 38.0°C or lab confirmed viral\u002Fbacterial\u002Ffungal infection (PCR) or symptoms suggestive of an infection)\n   * Received oral or IV antibiotics within \\\u003C7 days before administration.\n7. Any planned major surgery within the duration of the study (until follow-up visit) that is not related to the tumor, with the exception of any emergency surgeries.\n8. Prior allogeneic bone marrow transplantation or solid organ transplant.\n9. A history of anaphylaxis, history of allergic reaction(s), known allergy to one of the drugs or excipients administered as part of this study. Mild allergies without angio-edema or treatment need can be acceptable if deemed not of clinical significance (including allergy to animals or mild seasonal hay fever).\n10. Any other diseases, metabolic dysfunction, physical examination finding, or clinically significant laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug or that may affect the interpretation of the results or render the patient at high risk from treatment complications.",{"count":214,"type":21},32,[216],"EARLY_PHASE1","VARTUTRACE is a first-in-human PET\u002FCT molecular imaging study in patients with solid tumors. This study will investigate the biodistribution and pharmacology of two antibody fragments binding oncofetal Chondroitin Sulfate (CS).\n\nOncofetal CS are tumor-specific carbohydrate motifs present in proteoglycans and identified by VAR2 Pharmaceuticals as expressed during fetal development. Oncofetal CS reappears in the vast majority of cancers while remaining largely absent from normal tissues.\n\nVAR2 Pharmaceuticals recently developed antibodies specific for oncofetal CS. VARTUTRACE uses two of these as radiolabeled antibody fragments to study biodistribution, tumor accumulation, pharmacodynamics and clearance pathways in a diverse patient population.",[219,94,97,220,221,28,222,61,26,223,25,224,225,226],"Solid Tumor","Osteosarcoma","Chondrosarcoma","Head and Neck Squamous Cell Carcinoma","Pancreas Carcinoma","Glioblastoma","Soft Tissue Sarcoma (STS)","Breast Cancer",[228,229,230],"Basket-trial","Oncology","Solid tumors","2025-12-19",{"date":233,"type":34},"2025-12-29",{"date":235,"type":34},"2024-12-10",{"date":237,"type":21},"2026-09",{"name":239,"class":204},"Var2 Pharmaceuticals",{"id":241,"slug":242,"hasResults":11,"nctId":243,"briefTitle":244,"officialTitle":245,"acronym":246,"eligibilityCriteria":247,"healthyVolunteers":11,"sex":16,"minAge":85,"maxAge":163,"enrollmentInfo":248,"targetDuration":166,"studyType":22,"phases":4,"briefSummary":250,"conditions":251,"keywords":252,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":255,"lastUpdatePostDateStruct":256,"startDateStruct":258,"completionDateStruct":260,"leadSponsor":262,"locationsCount":132},"100572713","exploration-of-lymph-node-metastasis-and-tumor-deposit-in-the-posterior-gastric-mesentery-for-distal-gastric-cancer-100572713","NCT06736847","Exploration of Lymph Node Metastasis and Tumor Deposit in the Posterior Gastric Mesentery for Distal Gastric Cancer","Exploration of Lymph Node Metastasis and Tumor Deposit in the Posterior Gastric Mesentery Following D2 Lymphadenectomy Plus Complete Mesogastric Excision in Patients Who Received Distal Gastrectomy: A Prospective Observational Study","zydgc001","Inclusion Criteria:\n\n1. Aged older than 18 years and younger than 85 years\n2. Primary gastric adenocarcinoma confirmed by preoperative pathology result\n3. cT2-4N0-3M0 at preoperative evaluation according to the American Joint 8 Committee on Cancer (AJCC) Cancer Staging Manual 7th Edition\n4. Patients who received distal gastrectomy with D2 lymphadenectomy plus complete mesogastric excision\n5. American Society of Anesthesiologists (ASA) class I, II, or III\n6. Written informed consent\n\nExclusion Criteria:\n\n1. Negative preoperative biopsy\n2. Too late tumour stage or metastasis (cT4b\u002FM1)\n3. BMI\\>30 kg\u002Fm2\n4. Total gastrectomy or proximal gastrectomy\n5. previous neoadjuvant chemotherapy or radiotherapy\n6. Previous upper abdominal surgery\n7. Combined with other malignant diseases\n8. Reject operation",{"count":249,"type":21},200,"This study aims to evaluate lymph node metastasis and tumor deposit in the posterior gastric mesentery following distal gastrectomy with D2 lymphadenectomy plus complete mesogastric excision (CME) in gastric cancer.",[26],[170,253,254,173],"Lymph node dissection","Posterior gastric mesentery","2025-08-25",{"date":257,"type":34},"2025-09-02",{"date":259,"type":34},"2024-05-01",{"date":261,"type":21},"2027-12-31",{"name":181,"class":41},{"id":264,"slug":265,"hasResults":11,"nctId":266,"briefTitle":267,"officialTitle":268,"acronym":269,"eligibilityCriteria":270,"healthyVolunteers":11,"sex":16,"minAge":85,"maxAge":163,"enrollmentInfo":271,"targetDuration":273,"studyType":22,"phases":4,"briefSummary":274,"conditions":275,"keywords":276,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":255,"lastUpdatePostDateStruct":279,"startDateStruct":280,"completionDateStruct":281,"leadSponsor":282,"locationsCount":132},"100572101","analysis-of-tumor-deposit-at-the-fusion-site-of-the-right-gastric-mesentery-and-left-gastric-mesentery-in-the-patients-with-gastric-cancer-who-received-proximal-gastrectomy-100572101","NCT06728891","Analysis of Tumor Deposit at the Fusion Site of the Right Gastric Mesentery and Left Gastric Mesentery in the Patients With Gastric Cancer Who Received Proximal Gastrectomy","Tumor Deposit at the Fusion Site of the Right Gastric Mesentery and Left Gastric Mesentery in the Patients With Gastric Cancer Who Received Proximal Gastrectomy With D2 Lymphadenectomy Plus Complete Mesogastric Excision for Gastric Cancer: A Prospective Observational Study","zypg001","Inclusion Criteria:\n\n1. Aged older than 18 years and younger than 85 years\n2. Primary gastric adenocarcinoma confirmed by preoperative pathology result\n3. cT2-4aN0-3M0 at preoperative evaluation according to the American Joint 8 Committee on Cancer (AJCC) Cancer Staging Manual 8th Edition\n4. Patients undergoing proximal gastrectomy with D2 lymphadenectomy plus complete mesogastric excision\n5. American Society of Anesthesiologists (ASA) class I, II, or III\n6. Written informed consent\n\nExclusion Criteria:\n\n1. Negative preoperative biopsy\n2. Too late tumour stage or metastasis (cT4b\u002FM1)\n3. BMI\\>30 kg\u002Fm2\n4. previous neoadjuvant chemotherapy or radiotherapy\n5. Previous upper abdominal surgery\n6. Combined with other malignant diseases\n7. Reject operation",{"count":272,"type":21},100,"3 Years","This study aims to evaluate the tumor deposit at the fusion site of the right gastric mesentery and left gastric mesentery in the patients with gastric cancer who received proximal gastrectomy.",[26],[170,253,277,278],"Right gastric mesentery","Tumor deposit",{"date":257,"type":34},{"date":259,"type":34},{"date":261,"type":21},{"name":181,"class":41},{"id":284,"slug":285,"hasResults":11,"nctId":286,"briefTitle":287,"officialTitle":288,"acronym":289,"eligibilityCriteria":290,"healthyVolunteers":11,"sex":16,"minAge":85,"maxAge":4,"enrollmentInfo":291,"targetDuration":4,"studyType":54,"phases":293,"briefSummary":296,"conditions":297,"keywords":298,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":301,"lastUpdatePostDateStruct":302,"startDateStruct":304,"completionDateStruct":306,"leadSponsor":308,"locationsCount":132},"100601312","phase-1-detection-of-upper-gastrointestinal-tumour-depth-and-demarcation-using-systemic-administration-of-indocyanine-green-during-endoscopic-submucosal-dissection-100601312","NCT07108855","Detection of Upper Gastrointestinal Tumour Depth and Demarcation Using Systemic Administration of Indocyanine Green During Endoscopic Submucosal Dissection","Detection of Upper Gastrointestinal Tumour Depth and Demarcation by Quantified Fluorescence Molecular Endoscopy Using Systemic Administration of Indocyanine Green During Endoscopic Submucosal Dissection","BRIGHT","Inclusion Criteria:\n\n* Patients with confirmed superficial esophageal and\u002For gastric adenocarcinoma (T1) and are scheduled for ESD within the UMCG;\n* Age of 18 years or older;\n* Able to provide written informed consent.\n\nExclusion Criteria (contraindications for indocyanine green):\n\n* Known allergy to indocyanine green;\n* Known allergies to iodine, shellfish and\u002For clams;\n* eGFR \\\u003C 30 mL\u002Fmin\u002F1.73 m2;\n* Pregnancy or breastfeeding;\n* Hyperthyroidism.\n\n  * Severe liver disease (ascites and cirrhosis).",{"count":292,"type":21},10,[294,295],"PHASE1","PHASE2","Endoscopic submucosal dissection (ESD) is a relatively new technique to treat superficial cancers in the upper gastrointestinal (GI) tract. Previous studies reported high en bloc resection rates (95%-97%). However, R0 resection rates (84.5%) suggest that the tumour is not radically removed in all cases, resulting in a risk of tumour recurrence. One of the key challenges is the limited accuracy in determining the depth of cancer invasion. To reduce the risk of tumour recurrence, the endoscopist would greatly benefit from proper and complete visualization of the tumour margin and depth during ESD. Several studies have shown that near-infrared quantified fluorescence molecular endoscopy (qFME) could serve as a red flag detection method and might be a useful imaging tool for tumour demarcation in the upper GI tract. The aim of this study is to evaluate the feasibility of ICG-enhanced near-infrared qFME to determine tumour demarcation and tumour depth in upper GI tumours (e.g. superficial esophageal and\u002For gastric adenocarcinoma (T1)) during ESD.",[61,26],[299,300],"Indocyanine Green (ICG)","Fluorescence Molecular Endoscopy","2025-08-04",{"date":303,"type":34},"2025-08-07",{"date":305,"type":21},"2025-09-01",{"date":307,"type":21},"2027-08-01",{"name":309,"class":41},"University Medical Center Groningen",{"id":311,"slug":312,"hasResults":11,"nctId":313,"briefTitle":314,"officialTitle":315,"acronym":4,"eligibilityCriteria":316,"healthyVolunteers":11,"sex":16,"minAge":85,"maxAge":51,"enrollmentInfo":317,"targetDuration":4,"studyType":54,"phases":319,"briefSummary":320,"conditions":321,"keywords":4,"overallStatus":322,"whyStopped":4,"lastUpdateSubmitDate":323,"lastUpdatePostDateStruct":324,"startDateStruct":326,"completionDateStruct":328,"leadSponsor":330,"locationsCount":132},"100588676","phase-3-a-study-of-disitamab-vedotin-combined-with-tislelizumab-and-chemotherapy-versus-tislelizumab-combined-with-chemotherapy-in-her2-low-advanced-gastric-or-gastroesophageal-junction-adenocarcinoma-100588676","NCT06944496","A Study of Disitamab Vedotin Combined With Tislelizumab and Chemotherapy Versus Tislelizumab Combined With Chemotherapy in HER2-Low Advanced Gastric or Gastroesophageal Junction Adenocarcinoma","A Phase III, Randomized Trial Comparing RC48 Plus Chemotherapy and Tislelizumab With Tislelizumab Plus Chemotherapy as First-line Treatment in Participants With HER2 Low Advanced Gastric or Gastrioesophageal Junction Adenocarcinoma (RC48-C039)","Inclusion Criteria:\n\n* Voluntarily consent to participate in the study and sign the informed consent form\n* Expected survival period \\>12 weeks\n* ECOG Performance Status 0 or 1\n* Histologically confirmed unresectable locally advanced, metastatic, or recurrent gastric or gastroesophageal junction adenocarcinoma\n* No prior systemic therapy for locally advanced or metastatic gastric cancer\n* HER2-low expression\n* At least one assessable lesion according to RECIST v1.1 criteria\n* Adequate organ function\n* For female subjects: They should be surgically sterilized, postmenopausal, or agree to use a medically approved contraceptive method (such as an intrauterine device, contraceptive pill, or condom) during the study treatment period and for 6 months after the end of the study treatment. A blood pregnancy test must be negative within 7 days before the study medication is administered, and they must not be breastfeeding\n* For male subjects: They should be surgically sterilized or agree to use a medically approved contraceptive method during the study treatment period and for 6 months after the end of the study treatment\n* Able to understand the study requirements and willing to comply with the study and follow-up procedures\n\nExclusion Criteria:\n\n* Presence of central nervous system (CNS) metastasis and\u002For carcinomatous meningitis\n* Peripheral neuropathy \\> Grade 1\n* Tumor lesions with a tendency to bleed\n* Uncontrolled diarrhea\n* Bone metastases with a risk of paraplegia\n* Past or current interstitial lung disease, or presence of drug-induced pneumonia, radiation pneumonia, or severely impaired lung function\n* Other malignancies within 5 years before the first dose, except for those expected to be cured with treatment (e.g., adequately treated thyroid cancer, cervical carcinoma in situ, basal or squamous cell skin cancer, or ductal carcinoma in situ of the breast treated with curative surgery)\n* Pregnant or breastfeeding women",{"count":318,"type":21},616,[192],"The purpose of this study is to evaluate the efficacy and safety of \\*\\*Disitamab Vedotin combined with Tislelizumab and CAPOX versus Tislelizumab combined with CAPOX\\*\\* as first-line treatment for patients with HER2-low advanced gastric or gastroesophageal junction adenocarcinoma.",[26],"NOT_YET_RECRUITING","2025-04-23",{"date":325,"type":34},"2025-04-25",{"date":327,"type":21},"2025-05-15",{"date":329,"type":21},"2030-05-15",{"name":203,"class":204},{"id":332,"slug":333,"hasResults":11,"nctId":334,"briefTitle":335,"officialTitle":336,"acronym":4,"eligibilityCriteria":337,"healthyVolunteers":11,"sex":16,"minAge":85,"maxAge":4,"enrollmentInfo":338,"targetDuration":273,"studyType":22,"phases":4,"briefSummary":340,"conditions":341,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":345,"lastUpdatePostDateStruct":346,"startDateStruct":348,"completionDateStruct":350,"leadSponsor":352,"locationsCount":132},"100570087","the-correlation-between-blood-concentration-of-sintilimab-and-efficacy-and-adverse-reactions-in-patients-with-advanced-gastric-cancer-100570087","NCT06702683","The Correlation Between Blood Concentration of Sintilimab and Efficacy and Adverse Reactions in Patients with Advanced Gastric Cancer","Study on the Correlation Between Blood Concentration of Sintilimab and Related Predictors with Efficacy and Adverse Reactions in Patients with Advanced Gastric Cancer","Inclusion Criteria:\n\nA. Patients who were diagnosed with gastric adenocarcinoma or gastroesophageal junction adenocarcinoma; B. Patients who plan to be treated with Sintilimab; C.ECOG score of 0-2; D. Expected survival ≥3 months; E. The patient who have good compliance, follow-up, and can cooperate with relevant treatment and examination; F. Agree to participate in the study and sign the informed consent\n\nExclusion Criteria:\n\nA. Patients who clinical information and data are incomplete; B. Patients who treated with immune checkpoint inhibitors within 6 months",{"count":339,"type":21},112,"Compared with other anti-tumor drugs, immune checkpoint inhibitors (ICIs) have their own unique pharmacokinetics (PK) and pharmacodynamics (PD), and affect patient clinical outcomes. However, at present, the data on the PK and PD characteristics of ICIs in the Chinese population are still lacking, thus further clinical trials are needed to verify them. At the same time, a large proportion of patients have no response to ICIs or the efficacy is poor, and even bring greater side effects, so it is particularly important to find effective biomarkers to predict the efficacy and adverse reactions of patients with ICIs treatment.The purpose of this study is to explore the correlation between blood concentration of Sintilimab and related predictors with efficacy and adverse reactions in patients with advanced gastric cancer so as to provide clinical reference for individualized treatment of patients with gastric cancer.",[26,342,343,344],"Gastric Neoplasm","Gastric (cardia, Body) Cancer","Gastric Cancer Adenocarcinoma Metastatic","2024-11-21",{"date":347,"type":34},"2024-11-25",{"date":349,"type":34},"2023-02-17",{"date":351,"type":21},"2025-12-31",{"name":353,"class":41},"Lin Liu"]